Form D · Biotechnology
Kiadis Pharma N.V.
Amsterdam, P7 · CIK 0001780328
Offering snapshot reported Jun 26, 2019 · SEC filing
- Reported sold
- $18.4M Offering amount: $18.4M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 5, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2019 | Initial | $18,352,460 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-342850
Source: Form D, filed Jun 26, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott A. Holmes | Executive |
| James Joy | Executive |
| Martijn Kleijwegt | Director |
| Arthur Lahr | Executive |
| Berndt Modig | Director |
| Subhanu Saxena | Director |
| Mark Schaefer | Executive |
| Otto Schwarz | Director |
| Dr. Robert Soiffer | Director |
| Mark Wegter | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Paasheuvelweg 25 A
Amsterdam, P7, 1105 BP
Amsterdam, P7, 1105 BP